pharmaceutical investing Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
pharmaceutical investing Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
pharmaceutical investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
pharmaceutical investing Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
pharmaceutical investing Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery
Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer
Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services
QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance
